Authorizing Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE Parliamentary submission
DATE 2014-10-28
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE  Parliamentary submission
DATE  2015-05-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE
Parliamentary submission

DATE
2014-06-11

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image of text and diagrams]
Bill C-45: The Cannabis Act

https://policybase.cma.ca/link/policy13861

POLICY TYPE: Parliamentary submission
DATE: 2018-04-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Canada’s lower-risk cannabis use guidelines (LRCUG)

https://policybase.cma.ca/link/policy13726

POLICY TYPE: Policy endorsement
DATE: 2017-05-26
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase
https://policybase.cma.ca/link/policy11129

POLICY TYPE          Parliamentary submission
DATE                2014-05-15
TOPICS              Health care and patient safety
                     Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

CMA POLICY

Cannabis for Medical Purposes

The Canadian Medical Association (CMA), has always recognized the unique requirements of those individuals suffering from terminal illness or chronic diseases for which conventional therapies have not been effective and for whom treatment of any kind is risky.

There is a vast number of studies, anecdotal evidence to support cannabis for medical purposes, with varying degrees of validity for many patients, and the need to study and understand its effects.

While the development of new cannabis varieties to overcome side effects has been studied, less information is available on the management of chronic pain.

Pharmaceutical companies should be encouraged to consider converting their pain-killer pills to cannabis-based drugs.

The CMA encourages a national study to determine the potential for cannabis in the management of chronic pain.

The CMA urges the following recommendations:

1. Increase support for the strengthening of scientific knowledge about the medical use of cannabis. The CMA recommends the provision of support to acute medical, research and university institutions to improve the evidence base for the medical use of cannabis.

2. Appraise the economic and social impact of cannabis use in Canada.

3. Increase support for implementation of the regulations for medical purposes.

The CMA urges the following recommendations:

1. Increase support for the strengthening of scientific knowledge about the medical use of cannabis. The CMA recommends the provision of support to acute medical, research and university institutions to improve the evidence base for the medical use of cannabis.

2. Appraise the economic and social impact of cannabis use in Canada.

3. Increase support for implementation of the regulations for medical purposes. In their letter, dated 3 June 2004, the College of Physicians of Ont. and the College of Physicians of Que., note that the College of Physicians of Ont. and the College of Physicians of Que. support the CMA's recommendations.
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology – Prescription Drugs: Clinical Trials and Approval
https://policybase.cma.ca/link/policy0437

POLICY TYPE
Parliamentary submission

DATE
2012-05-09

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE  Parliamentary submission
DATE  2022-05-13
TOPICS  Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA Response: Health Canada's Medical Marijuana Regulatory Proposal
CMA Policybase - Canadian Medical Association
CMA Response: Health Canada’s Medical Marijuana Regulatory Proposal
https://policybase.cma.ca/link/policy10702

POLICY TYPE                  Parliamentary submission
DATE                        2013-02-28
TOPICS                      Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE Response to consultation
DATE 2017-06-28
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents

CMA Submission:
CMA's Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the House of Commons Standing Committee on Health

February 15, 2018
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE  
Response to consultation

DATE  
2015-06-08

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the House of Commons Standing Committee on Health: Drug Shortages
https://policybase.cma.ca/link/policy10382

POLICY TYPE
Parliamentary submission

DATE
2012-03-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125

POLICY TYPE: Parliamentary submission
DATE: 2014-03-26
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy3617

POLICY TYPE          Parliamentary submission
DATE                2017-04-06
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission to the study of Bill C-37
An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts

Submission to the Senate Standing Committee on Legal and Constitutional Affairs

April 6, 2017